Adagene

elsewhere's corpus doesn't genuinely cover Adagene. The retrieval material under this name actually describes 天辰生物 (Tianchen Biologics, 01779.HK) — a Suzhou-based allergy and autoimmune drug developer founded in 2020, which listed on the HKEX on June 5, 2026 with backing from Qiming Venture Partners — a different company entirely. For Adagene (天演药业) itself, elsewhere has no subject-level reporting to draw a profile from, so nothing further can be stated here.